[Brokerage Focus] Zhongtai Securities maintains a 'shareholding' rating for Remegen (09995), indicating a significant improvement in its third-quarter profitabilty both year-on-year and quarter-on-quarter.

Kingu Financial News | Zhongtai Securities issued a research report, remegen (09995) recorded a third-quarter revenue of 0.47 billion yuan, a growth of +34.6% compared to the same period last year; total revenue for January-September 2024 was 1.21 billion yuan, a 57.10% growth year-on-year; net income in the third quarter was a loss of 0.29 billion yuan, a 32.6% decrease in losses compared to the second quarter. The bank pointed out that Tai Tesip and Videsituximab's high-quality academic research results continue to be published in international societies and journals, accumulating evidence-based medicine to promote the continued growth in sales domestically, with revenue in the first three quarters maintaining robust and rapid growth, in line with expectations. 20

Golden Guard Financial NewsNov 6 04:04 ET

RemeGen Co., Ltd. (HKG:9995) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Simply Wall StOct 31 20:47 ET

Hong Kong stock market sectors generally fell, with trading volume increasing to 160 billion Hong Kong dollars. Institutions believe Hang Seng Index at 19,500 points is worth investing in.

Produced jointly by Zhongtai International and CaiLian News.

cls.cnOct 30 19:08 ET

HK stocks unusual movement | Remegen (09995) surged more than 10%, the company's main business income greatly increased, and the third-quarter loss narrowed by more than 30% month-on-month.

Remegen (09995) rose by more than 10%. As of the time of publication, it rose by 10.8% to HK$16, with a turnover of HK$78.6233 million.

Zhitong FinanceOct 29 23:53 ET

HK Stock Market News | Some pharmaceutical stocks rose in early trading, as the national medical insurance negotiations are expected to start soon. Institutions say that sector catalyst events will be intensive in the fourth quarter.

Some pharmaceutical stocks rose in the morning session, as of the time of publication, Remegen (09995) rose by 8.73%, to 15.7 Hong Kong dollars; Keji Pharmaceutical-B (02171) rose by 6.47%, to 15.7 Hong Kong dollars; Aneuro-B (01952) rose by 2.11%, to 31.5 Hong Kong dollars; Fosun Pharma (02196) rose by 3.7%, to 15.12 Hong Kong dollars.

Zhitong FinanceOct 29 22:06 ET

RemeGen Posts Loss in Q3; Shanghai Shares Rise 4%

MT NewswiresOct 29 21:56 ET